Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25423
Title: Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative.
Austin Authors: Corboy, Greg;Othman, Jad;Lee, Linda;Wei, Andrew;Ivey, Adam;Blombery, Piers;Agarwal, Rishu ;Fong, Chun Yew ;Brown, Anna;Scott, Hamish;Grove, Carolyn;Louw, Alison;Enjeti, Anoop;Iland, Harry;Paul, Cheryl;Bohlander, Stefan;Kakadia, Purvi;Horan, Martin;Stevenson, William
Affiliation: Australasian Leukaemia and Lymphoma Group (ALLG), Richmond, Vic, Australia
Department of Haematology and Molecular Medicine, NSW Health Pathology - Hunter, John Hunter Hospital, Newcastle, NSW, Australia
LabPlus, Auckland City Hospital, Grafton, New Zealand
Department of Molecular Medicine and Pathology, The University of Auckland, Grafton, New Zealand
Molecular Haematology, NSW Health Pathology, Royal North Shore Hospital, St Leonards, NSW, Australia
Department of Haematology, Royal North Shore Hospital, St Leonards, NSW, Australia
Leukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, The University of Auckland, Grafton, New Zealand
Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP), St Leonards, NSW, Australia
Department of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
Australasian Leukaemia and Lymphoma Group (ALLG), Richmond, Vic, Australia
PathWest Laboratory Medicine, Perth, WA, Australia
Sir Charles Gairdner Hospital, Perth, WA, Australia
Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia
School of Medicine, University of Adelaide, Adelaide, SA, Australia
ACRF Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia
Clinical Haematology
Peter MacCallum Cancer Centre, Parkville, Vic, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic, Australia
Department of Haematology, Alfred Health, Prahran, Vic, Australia
Department of Pathology, Alfred Health, Prahran, Vic, Australia
Leukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, The University of Auckland, Grafton, New Zealand
Issue Date: Jun-2021
metadata.dc.date: 2020-11-30
Publication information: Pathology 2021; 53(4): 487-492
Abstract: Accurate classification of acute myeloid leukaemia (AML) has become increasingly reliant on molecular characterisation of this blood cancer. Throughout Australia and New Zealand massively parallel sequencing (MPS) is being adopted by diagnostic laboratories for the routine evaluation of patients with AML. This technology enables the surveying of many genes simultaneously, with many technical advantages over single gene testing approaches. However, there are many variations in wet and dry lab MPS procedures, which raises the prospect of discordant results between laboratories. This study compared the results obtained from MPS testing of ten diagnostic AML bone marrow aspirate samples sent to eight participating laboratories across Australasia. A reassuringly high concordance of 94% was observed with regard to variant detection and characterisation of pathogenicity. The level of discordance observed, although low, demonstrates the need for ongoing assessment of concordance between diagnostic testing laboratories through quality assurance programs.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25423
DOI: 10.1016/j.pathol.2020.08.019
PubMed URL: 33272691
Type: Journal Article
Subjects: Genomics
haematology
leukaemia
quality assurance
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on Dec 8, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.